Subcutaneous apomorphine infusion in Parkinson's disease: does it have a role?

Apomorphine is a potent dopamine agonist at both D1 and D2 receptors and has been used successfully for treating the 'on/off' phenomenon in Parkinson's disease. We report our experience with apomorphine in treating the 'on/off' phenomenon in L-dopa responsive idiopathic Park...

Full description

Saved in:
Bibliographic Details
Published in:Postgraduate medical journal 1994-05, Vol.70 (823), p.344-346
Main Authors: Muhiddin, K. A., Roche, M. T., Pearce, V. R.
Format: Article
Language:English
Subjects:
Activities of Daily Living
Aged
Aged, 80 and over
Anticonvulsants. Antiepileptics. Antiparkinson agents
Apomorphine - administration & dosage
Biological and medical sciences
Humans
Infusion Pumps
Male
Medical sciences
Middle Aged
Neuropharmacology
Parkinson Disease - drug therapy
Pharmacology. Drug treatments
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Apomorphine is a potent dopamine agonist at both D1 and D2 receptors and has been used successfully for treating the 'on/off' phenomenon in Parkinson's disease. We report our experience with apomorphine in treating the 'on/off' phenomenon in L-dopa responsive idiopathic Parkinson's disease. Thirteen such patients were commenced on apomorphine infusions. Their mean age was 69 (range 53-80) years and the mean duration of the disease was 15 (range 6-28) years. The clinical response to apomorphine was good in four patients, fair in two, unchanged in five and worse in two. Activities of daily living improved in six, were unchanged in five and worse in two. When the response was poor or showed no change, apomorphine was discontinued. In addition, apomorphine was also discontinued in three patients who had had a fair/good response but suffered side effects of hallucinations, delusions and psychosis, lack of cooperation or found the pump inconvenient. Apomorphine was continued in only three patients out of 13.
ISSN:0032-5473
1469-0756
DOI:10.1136/pgmj.70.823.344